Christopher Fenimore

Executive Vice President, Finance and Chief Financial Officer (Principal Financial Officer), Regeneron Pharmaceuticals

In the seat. First published here October 28, 2026; built from records as of October 28, 2026.

Christopher Fenimore signed the annual report of Regeneron Pharmaceuticals as Executive Vice President, Finance and Chief Financial Officer (Principal Financial Officer); the report was filed on February 4, 2026, the most recent filing in the record that ties Christopher Fenimore to the seat.¹

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Regeneron Pharmaceuticals (REGN) Pharmaceutical Preparations	Executive Vice President, Finance and Chief Financial Officer (Principal Financial Officer)	In the seat	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

February 4, 202610-K filed
Christopher Fenimore signed the annual report of Regeneron Pharmaceuticals on Form 10-K as Executive Vice President, Finance and Chief Financial Officer (Principal Financial Officer), filed February 4, 2026.
/s/ CHRISTOPHER FENIMORE Executive Vice President, Finance and Chief Financial Officer (Principal Financial Officer)
[1] Annual report on Form 10-K by Regeneron Pharmaceuticals, filed with the SEC on February 4, 2026. Read the filing. The record at CFO Tribune.

Sources

Annual report on Form 10-K, Regeneron Pharmaceuticals. U.S. Securities and Exchange Commission, EDGAR, filed February 4, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Christopher Fenimore wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.